慢性乙型肝炎治愈临床研究进展

摘要/Abstract

摘要： 核苷(酸)类似物及长效干扰素是临床常用的HBV抗病毒治疗药物。由于HBV cccDNA及整合到人体基因组的HBV DNA难以清除,多数患者需要接受长期抗病毒治疗。随着对HBV生命周期及致病机制的深入研究,有关HBV生物标志物及抗病毒新药的研发也进入了活跃期。HBV RNA、核心抗原相关抗原、不同类型乙型肝炎表面抗原是评价抗病毒效果及能否安全停药的潜在指标。肝细胞进入抑制剂、HBV核衣壳抑制剂、RNA干扰、治疗性疫苗、免疫调控等多种乙型肝炎新药的加速研发给乙型肝炎临床治愈带来了希望。

关键词: 慢性乙型肝炎, 抗病毒治疗, 生物标志物, 临床治愈

文夏杰, 鲁凤民, 贾继东. 慢性乙型肝炎治愈临床研究进展[J]. 肝脏, 2022, 27(9): 947-949.

参考文献

[1] Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers, 2018, 4: 18035.
[2] Liu Y, Liu H, Hu Z, et al. Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. Hepatology, 2020, 71(2): 463-476.
[3] Fung S, Choi H, Gehring A, et al. Getting to HBV cure: The promising paths forward. Hepatology, 2022, 76(1): 233-250.
[4] Wang X, Chi X, Wu R, et al. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J, 2021, 18(1): 4.
[5] Gao Y, Li Y, Meng Q, et al. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?. J Clin Microbiol, 2017, 55(10): 2972-2982.
[6] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol, 2018, 99-100: 71-78.
[7] Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut, 2021, 70(4): 775-783.
[8] Farag MS, van Campenhout M, Pfefferkorn M, et al. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clin Infect Dis, 2021, 72(2): 202-211.
[9] 刘燕娜,樊蓉,杨瑞锋,等. 慢性HBV感染者血清HBV RNA检测及临床应用的专家共识. 中华肝脏病杂志, 2022, 30(05): 505-512.
[10] Kimura T, Ohno N, Terada N, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem, 2005, 280(23): 21713-21719.
[11] Wong DK, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int, 2017, 37(7): 995-1001.
[12] Matsumoto A, Tanaka E, Minami M, et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res, 2007, 37(8): 661-666.
[13] Pfefferkorn M, Schott T, Bohm S, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol, 2021, 74(2): 283-292.
[14] 庄辉. 血清HBV大、中、小表面蛋白检测的临床意义. 临床肝胆病杂志, 2022, 38(03): 528-531.
[15] Li W, Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol, 2016, 64(1 Suppl): S32-S40.
[16] Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol, 2016, 65(3): 490-498.
[17] Rensen PC, van Leeuwen SH, Sliedregt LA, et al. Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. J Med Chem, 2004, 47(23): 5798-5808.
[18] Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence, 2022, 13(1): 1111-1132.
[19] Liu J, Li T, Zhang L, et al. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review. Hepatology, 2019, 70(3): 1045-1055.
[20] Yang S, Zeng W, Zhang J, et al. Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?. Emerg Microbes Infect, 2021, 10(1): 1545-1554.
[21] Bazinet M, Pantea V, Placinta G, et al. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy. Gastroenterology, 2020, 158(8): 2180-2194.
[22] Gane EJ, Kim HJ, Visvanthan K, et al. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. Hepatology, 2021, 74(4): 1737-1749.
[23] Lok AS, Pan CQ, Han SH, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol, 2016, 65(3): 509-516.
[24] Boni C, Janssen H, Rossi M, et al. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. Gastroenterology, 2019, 157(1): 227-241.